On April 22, 2022, Joel Schneider, Chief Operating Officer of Solid Biosciences Inc., notified the company of his intent to resign to accept a role as chief executive officer of a privately-held novel, viral-based gene therapy platform company. Such resignation is expected to be effective as of May 27, 2022, after a period of transitioning his duties to internal successors.